Kidney disease drug dosing study completed
NCT ID NCT07032272
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at how the drug remibrutinib behaves in people with severe kidney problems compared to healthy people. Researchers measured drug levels in blood and urine to understand how the kidneys process it. The goal is to help doctors decide the right dose for patients with kidney disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- remibrutinib (a tablet drug)
- What this could lead to
- If successful, this study could help doctors determine the right dose of remibrutinib for patients with severe kidney problems.
- What could go wrong
- This is a very early, small study (16 people) focused on drug levels and safety, not on treating any disease. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE AND CHRONIC INFLAMMATORY DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinical Pharmacology of Miami LLC
Miami, Florida, 33014-3616, United States
-
Genesis Clinical Research
Tampa, Florida, 33614, United States
-
Orlando Clinical Research Center
Orlando, Florida, 32809, United States
-
Panax Clinical Research
Miami Lakes, Florida, 33014, United States